Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial
– Combination therapy cohort initiated in Palleon’s ongoing study to evaluate safety, pharmacodynamic effects, and antitumor activity of its lead glyco-immunology candidate in patients with advanced cancer
– E-602 being evaluated in combination with cemiplimab (Libtayo®) as part of clinical trial supply agreement with Regeneron
Excerpt from the Press Release:
WALTHAM, Mass.–(BUSINESS WIRE)–Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the first patient has been dosed in the combination therapy cohort of the Phase 1/2 clinical trial for E-602, its lead candidate from the EAGLE (Enzyme Antibody Glyco-Ligand Editing) oncology platform. The GLIMMER-01 (Glycan-Mediated Immune Regulation) trial is designed to study E-602 as a monotherapy and in combination with cemiplimab (anti-PD-1) in patients with advanced cancers.
“With E-602, we are investigating an entirely new approach to oncology, one that we feel has potential benefits both as a monotherapy and in combination with other anti-cancer agents,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “We are pleased to work with Regeneron to evaluate E-602 in combination with cemiplimab. We expect this trial to provide valuable information as we look to understand the benefits that targeting sialoglycans can bring to advancing the field of oncology and ultimately improving the outlook for patients.”
E-602 is a first-in-class glyco-immune checkpoint inhibitor developed by Palleon and designed to enzymatically degrade immunosuppressive cell-surface sugars on tumors and immune cells. GLIMMER-01 is an open-label, single-arm, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic, and antitumor activity of E-602. Regeneron is providing cemiplimab for the trial as part of a clinical supply agreement initiated earlier this year.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?